Ketamine Increases Brain PDE4 Binding in Rats and Monkeys

Molecular Mechanisms of Rapid Antidepressant Response

Major depressive disorder affects more than 300 million people globally, yet many patients fail to achieve remission with standard monoaminergic medications that target traditional neurotransmitter pathways [1]. Intravenous racemic ketamine has emerged as a rapid acting intervention for treatment resistant cases, with meta analyses of randomized controlled trials showing it is more effective than theta burst stimulation (a non invasive neuromodulation technique) within the first week of administration [2]. In these difficult to treat populations, ketamine and its intranasal enantiomer, esketamine, have demonstrated the ability to reduce functional impairment and improve patient reported quality of life [3, 4]. However, the clinical utility of this N methyl D aspartate (NMDA) receptor antagonist is often limited by transient adverse events, including dissociation (a sense of detachment from one’s environment) and acute blood pressure elevations [5]. A new study now offers fresh insights into the underlying molecular mechanisms that may explain these rapid clinical improvements.

The Role of cAMP and PDE4 in Depression

The intracellular signaling molecule cyclic adenosine monophosphate (cAMP) serves as a critical secondary messenger in the brain, facilitating the transmission of signals that regulate synaptic plasticity and mood. The enzyme responsible for terminating cAMP activity is phosphodiesterase-4 (PDE4), which breaks down the messenger to maintain cellular homeostasis. Because PDE4 directly controls the duration and intensity of cAMP signaling, it has emerged as a primary molecular target for understanding the pathophysiology of mood disorders. Previous clinical research using positron emission tomography (PET) imaging has demonstrated that whole brain binding of the radioligand 11C-rolipram to PDE4 was decreased in individuals with major depressive disorder, suggesting a fundamental deficit in this signaling pathway during depressive episodes. This deficit in enzyme binding likely reflects a broader downregulation of the cAMP signaling cascade, which is essential for maintaining the structural integrity of dendritic spines and synaptic connectivity in brain regions associated with emotional regulation.

The clinical relevance of this pathway is further underscored by its response to therapeutic intervention. While the initial deficit in PDE4 binding is a characteristic of the depressed state, longitudinal data indicate that eight weeks of antidepressant treatment rescued the decrease in 11C-rolipram binding in patients who achieved clinical improvement. This suggests that the normalization of cAMP signaling is a common downstream effect of successful antidepressant therapy. However, traditional monoaminergic medications require months to achieve these molecular and symptomatic changes. Ketamine, an N methyl D aspartate (NMDA) receptor antagonist, provides a distinct clinical profile characterized by robust, rapid acting antidepressant effects that manifest within hours. The researchers in the current study aimed to determine if ketamine could bypass the lengthy timeline of traditional drugs by rapidly modulating PDE4 and cAMP activity, potentially providing a molecular shortcut to clinical remission.

Quantifying Molecular Changes in Animal Models

To investigate the acute molecular effects of ketamine, the researchers conducted a series of experiments using rat and primate models to observe changes in brain signaling. The study aimed to determine whether ketamine infusion could rapidly increase cyclic adenosine monophosphate (cAMP) activity in rats and rhesus macaques. The researchers utilized positron emission tomography (PET) imaging with 11C-rolipram, a radioligand that targets all phosphodiesterase-4 (PDE4) subtypes. By measuring the binding of this tracer, the team could quantify the availability and activity of the enzyme responsible for degrading cAMP, thereby providing a proxy for intracellular signaling strength. This approach allows clinicians to visualize the dynamic state of second messenger systems that are otherwise inaccessible in a living subject.

The experimental protocol involved administering subanesthetic doses of ketamine, with rats receiving 10 mg/kg and rhesus macaques receiving 0.5 mg/kg. In the rat model, ketamine increased 11C-rolipram binding to PDE4 with a mean standardized uptake value (SUV) increase of 24% ± 14%. The standardized uptake value (a PET imaging metric that represents the ratio of the tracer activity concentration in a tissue region to the injected activity per unit of body weight) provides a normalized measure of drug uptake. The observed increase in binding among the rats ranged from 3% to 42% (p = 0.004), demonstrating a significant and rapid elevation in enzyme binding following the infusion.

Consistent results were observed in the primate subjects, further supporting the role of the cAMP pathway in ketamine's mechanism of action. In rhesus macaques, ketamine increased 11C-rolipram binding with a mean distribution volume (VT) increase of 14% ± 2%. The distribution volume (VT) is a pharmacokinetic parameter that describes the ratio of the concentration of the radioligand in the brain to its concentration in the plasma at equilibrium, serving as a precise measure of total binding site density. The range of the 11C-rolipram binding increase in monkeys was 12% to 16% (p = 0.003). These data indicate that ketamine rapidly modulates the same molecular targets that traditional antidepressants take weeks to influence, potentially explaining the accelerated clinical response seen in patients.

Targeting the PDE4B Subtype

To further refine the molecular target of ketamine, the researchers utilized a more specific radioligand, [18F]PF-06445974, which is preferential for the PDE4B subtype over PDE4D. While 11C-rolipram binds to all phosphodiesterase-4 subtypes, this targeted tracer allowed the team to isolate the activity of PDE4B, an enzyme variant strongly implicated in mood regulation and cognitive function. In the rhesus macaque model, ketamine increased [18F]PF-06445974 binding within one hour of infusion, demonstrating a rapid molecular response. The researchers observed a mean distribution volume (VT) increase of 28% ± 7% for this specific tracer. The distribution volume, which represents the ratio of radioligand concentration in the brain compared to plasma at equilibrium, showed an increase ranging from 16% to 37% (p = 0.008). These findings suggest that the PDE4B subtype may be a primary mediator of the intracellular signaling changes triggered by ketamine, offering a more specific target for future drug development.

To ensure that these observations reflected true changes in enzyme binding rather than artifacts of altered physiology, the study employed a rigorous control using 11C-rolipram in the rat model. Unlike its counterpart, 11C-rolipram has no specific binding to PDE4 and was used to control for the potential effects of ketamine on cerebral blood flow and the delivery of the radioligand to brain tissue. This is a critical distinction, as ketamine is known to have hemodynamic effects that could theoretically confound PET imaging results. When this control tracer was administered, no consistent effects were observed for ketamine in rats, indicating that the increases seen with the active tracers were not the result of hemodynamic changes or altered tracer kinetics. This distinction strengthens the evidence that ketamine directly modulates the cyclic adenosine monophosphate (cAMP) pathway through phosphodiesterase-4, providing a specific molecular mechanism that clinicians can associate with the drug's rapid antidepressant efficacy.

Clinical Implications for Future Therapeutics

The observation that ketamine infusion rapidly increases cyclic adenosine monophosphate (cAMP) activity provides a critical link between immediate molecular signaling and the drug's clinical efficacy. While traditional antidepressants often require weeks to restore cAMP levels, the data from this study indicate that ketamine achieves a similar molecular shift within one hour of administration. Specifically, the researchers found that ketamine infusion rapidly increases cAMP activity, as evidenced by the significant rise in phosphodiesterase-4 (PDE4) binding across both rat and monkey models. This immediate surge in intracellular signaling suggests that increased cAMP activity may be an underlying mechanism for ketamine’s rapid antidepressant effects, offering a biological explanation for why patients often report symptom relief shortly after a single subanesthetic dose.

These findings further support a common pathway for cAMP and antidepressant action, reinforcing the hypothesis that modulating this second messenger system is essential for mood stabilization. By identifying the specific involvement of the PDE4B subtype, the study opens a new avenue for drug development that could bypass the side effects associated with N methyl D aspartate (NMDA) receptor antagonism, such as dissociation or potential for abuse. The researchers conclude that PDE4 inhibition, particularly PDE4B, may be an effective and rapid acting antidepressant mechanism. For clinicians, this suggests that future therapeutics targeting PDE4B could potentially replicate the rapid acting benefits of ketamine while offering a more favorable safety profile for the long term management of major depressive disorder, moving the field closer to targeted molecular interventions that do not require the intensive monitoring associated with ketamine administration.

References

1. Słupski J, Mechlińska A, Włodarczyk A, et al. Appetite measures as correlates of clinical response in mood disorders treated with ketamine: systematic review. Frontiers in Nutrition. 2025. doi:10.3389/fnut.2025.1616859

2. Terao I, Kodama W. Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta-analyses of randomized controlled trials.. PCN reports : psychiatry and clinical neurosciences. 2024. doi:10.1002/pcn5.70042

3. Ji IS, Cheng MCH, Teopiz KM, et al. The effects of ketamine and esketamine on functional outcomes in major depressive disorder and treatment-resistant depression: A systematic review.. Journal of psychiatric research. 2026. doi:10.1016/j.jpsychires.2025.10.056

4. Cheng MCH, Dri CE, Ballum H, et al. The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review.. Journal of affective disorders. 2025. doi:10.1016/j.jad.2025.04.119

5. Guo H, Tang L, He M, et al. Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis.. Frontiers in pharmacology. 2025. doi:10.3389/fphar.2025.1681060